Imaging nigral pathology and clinical progression in Parkinson's disease

Movement Disorders

Volumn 27, Issue 13, 2012, Pages 1636-1643

  Du, Guangwei ^a   Lewis, Mechelle M ^a   Sen, Suman ^a   Wang, Jianli ^a   Shaffer, Michele L ^a   Styner, Martin ^b,c   Yang, Qing X ^a   Huang, Xuemei ^a,c  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Brooks Computer Science Building   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusion tensor imaging; Magnetic resonance imaging; Parkinson's disease; Substantia nigra; Transverse relaxation rate

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; FEMALE; FRACTIONAL ANISOTROPY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MEASUREMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; RELAXOMETRY; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANALYSIS OF VARIANCE; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA;

EID: 84870376463     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25182     Document Type: Article

References (46)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
2. Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122: 1437-1448.
3. Gorell JM, Ordidge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995; 45: 1138-1143.
4. Graham JM, Paley MN, Grunewald RA, et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123: 2423-2431.
5. Chan LL, Rumpel H, Yap K, et al. Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1383-1386.
6. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70: 1411-1417.
7. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378-1384.
8. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010; 257: 455-462.
9. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133: 3423-3433.
10. Du G, Lewis MM, Styner M, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011; 26: 1627-1632.
11. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009; 47: 435-441.
12. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007; 26: 590-596.
13. Lang AE, Mikulis D. A new sensitive imaging biomarker for Parkinson disease? Neurology 2009; 72: 1374-1375.
14. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
15. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499.
16. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
17. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
18. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994; 117: 501-507.
19. Lee CS, Schulzer M, Fuente-Fernandez R, et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 2004; 61: 1920-1925.
20. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68: 948-952.
21. Lee CS, Schulzer M, Mak E, et al. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology 1995; 45: 435-439.
22. Liu Z, Wang Y, Gerig G, et al. Quality control of diffusion weighted images. Medical Imaging 2010: advanced PACS-based imaging informatics and therapeutic applications. In: Proceedings of SPIE, August 1-5, 2010, San Diego, California, USA, 7628[76280J].
23. Salvador R, Pena A, Menon DK, et al. Formal characterization and extension of the linearized diffusion tensor model. Hum Brain Mapp 2005; 24: 144-155.
24. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006; 31: 1116-1128.
25. Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122: 1421-1436.
26. Vaillancourt DE, Spraker MB, Prodoehl J, Zhou XJ, Little DM. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging 2012; 33: 35-42.
27. Massey LA, Yousry TA. Anatomy of the substantia nigra and subthalamic nucleus on MR imaging. Neuroimaging Clin N Am 2010; 20: 7-27.
28. Rueckert D, Sonoda LI, Hayes C, et al. Nonrigid registration using free-form deformations: application to breast MR images. IEEE Trans Med Imaging 1999; 18: 712-721.
29. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann Neurol. 1992; 32 (Suppl): S10-S15.
30. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199-205.
31. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994; 36: 876-881.
32. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing, and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873.
33. Meadowcroft MD, Connor JR, Smith MB, et al. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J Magn Reson Imaging 2009; 29: 997-1007.
34. Gossuin Y, Roch A, Muller RN, et al. Relaxation induced by ferritin and ferritin-like magnetic particles: the role of proton exchange. Magn Reson Med 2000; 43: 237-243.
35. Gossuin Y, Hautot D, Muller RN, et al. Looking for biogenic magnetite in brain ferritin using NMR relaxometry. NMR Biomed 2005; 18: 469-472.
36. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1-25.
37. Dexter DT, Jenner P, Schapira AH, et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992; 32 (Suppl): S94-S100.
38. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515-520.
39. Zecca L, Casella L, Albertini A, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008; 106: 1866-1875.
40. Double KL, Gerlach M, Schunemann V, et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003; 66: 489-494.
41. Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003; 86: 1142-1148.
42. Schwarz ST, Rittman T, Gontu V, et al. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011; 26: 1633-1638.
43. Manova ES, Habib CA, Boikov AS, et al. Characterizing the mesencephalon using susceptibility-weighted imaging. AJNR Am J Neuroradiol 2009; 30: 569-574.
44. Oikawa H, Sasaki M, Tamakawa Y, et al. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 2002; 23: 1747-1756.
45. Kwon DH, Kim JM, Oh SH, et al. Seven-tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012; 71: 267-277.
46. Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012; 35: 48-55.